Efficacy of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.

被引：1
|
作者：
Laktionov, Konstantin K.
Arzumanyan, Alla L.
Bolotina, Larisa
Breder, Valeriy Vladimirovich
Buevich, Natalia N.
Danilova, Anastasia
Filippova, Elena A.
Kornietskaya, Anna
Kramchaninov, Mikhail M.
Kushniruk, Eugenia K.
Latipova, Dilorom H.
Moiseenko, Fedor Vladimirovich
Nikitina, Tatiana P.
Orlov, Sergey V.
Orlova, Rashida
Protsenko, Svetlana A.
Sarantseva, Ksenia A.
Stroyakovskiy, Daniil L.
Zinkovskaya, Anna V.
机构：
[1] N N Blokhin Russian Canc Res Ctr, Moscow, Russia
[2] Minist Hlth, Hertsen Moscow Oncol Res Inst, Natl Med Res Radiol Ctr, Moscow, Russia
[3] Natl Med Res Ctr Oncol n N Blokhin, Moscow, Russia
[4] N N Petrov Res Inst Oncol, St Petersburg, Russia
[5] Moscow Dept Hlth, Moscow City Oncol Hosp 62, Moscow, Russia
[6] Pavlov St Petersburg State Med Univ, R M Gorbacheva Mem Inst Children Hematol & Transp, St Petersburg, Russia
[7] St Petersburg Clin Res Ctr Specialized Types Med, St Petersburg, Russia
[8] City Clin Oncol Dispensary, St Petersburg, Russia
[9] Multinat Ctr Qual Life Res, St Petersburg, Russia
[10] St Petersburg State Univ, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21126
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
    Gonzalez, P.
    Ortega-Joaquin, N.
    Provencio Pulla, M.
    Garrido, C.
    Echave, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study
    Alberola, V.
    Gallego, O.
    Lopez-Vivanco, G.
    Mesia, C.
    Oramas, J.
    Trigo, J. M.
    Virizuela, J. A.
    Camps, C.
    Regueiro, P.
    Massuti, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] The results of the treatment with gefitinib (Iressa) in 89 patients with advanced non-small cell lung cancer (NSCLC)
    Skrickova, J
    Tomiskova, M
    Svobodnik, A
    Kaplanova, J
    Kadlec, B
    Palkova, I
    Babickova, L
    Stratil, D
    Nebesky, T
    LUNG CANCER, 2005, 49 : S376 - S376
  • [44] Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
    Tanaka, Kentaro
    Chamoto, Kenji
    Saeki, Sho
    Hatae, Ryusuke
    Ikematsu, Yuki
    Sakai, Kazuko
    Ando, Nobuhisa
    Sonomura, Kazuhiro
    Kojima, Shinsuke
    Taketsuna, Masanori
    Kim, Young Hak
    Yoshida, Hironori
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Hirano, Tomoko
    Matsuda, Fumihiko
    Hirai, Toyohiro
    Nishio, Kazuto
    Sakagami, Takuro
    Fukushima, Masanori
    Nakanishi, Yoichi
    Honjo, Tasuku
    Okamoto, Isamu
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (675)
  • [45] EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
    Dixmier, A.
    Debieuvre, D.
    Raspaud, C.
    Auliac, J. B.
    Benoit, N.
    Bombaron, P.
    Asselain, B.
    Dumont, A.
    Lamoureux, P.
    Goyard, N.
    Moro-Sibilot, D.
    Perol, M.
    Barlesi, F.
    Valette, C. Audigier
    ANNALS OF ONCOLOGY, 2018, 29 : 532 - 532
  • [46] Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
    Caponnetto, S.
    Mancini, M.
    Manai, C.
    Magri, V.
    Iannantuono, G. M.
    Pellegrino, D.
    Mosillo, C.
    Piesco, G.
    Pomati, G.
    Scagnoli, S.
    Urbano, F.
    Verkhovskaya, S.
    Barchiesi, G.
    Zancla, S.
    Cortesi, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] An observational study of the efficacy and safety of nivolumab in pretreated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group Clinical Practice.
    Manrique, Carmen Areses
    Afonso, Francisco J. Afonso
    Rivera, Francisca Vazquez
    Quintela, Martin Lazar
    Vazquez-Estevez, Sergio
    Calvo, Ovidio Fernandez
    Simo, Rocio Vilchez
    Gonzalez, Jorge Garcia
    Lopez, Eva Perez
    Mata, Jesus Garcia
    Herranz, Urbano Anido
    Rubio, Joaquin Casal
    Perez, Jose Luis Firvida
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] The Efficacy and Safety of Nivolumab, Pembrolizumab, and Atezolizumab in Treatment of Advanced Non-small Cell Lung Cancer
    Chen, Rui
    Tao, Yuquan
    Xu, Xin
    Shan, Liang
    Jiang, Hongyuan
    Yin, Qilei
    Pei, Lingyan
    Cai, Feng
    Ma, Lifang
    Yu, Yongchun
    DISCOVERY MEDICINE, 2018, 26 (143) : 155 - 166
  • [49] Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)
    Gettinger, S. N.
    Horn, L.
    Ramalingam, S. S.
    Spigel, D. R.
    Paz-Ares, L.
    Paik, P.
    Reck, M.
    Reckamp, K.
    Mazieres, J.
    Stinchcombe, T.
    Lynch, M.
    Brahmer, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S631 - S631
  • [50] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345